Skip to main content
SpringerLink
Log in

Pharmaceutical Policy in Pakistan

  • Chapter
  • First Online:
Pharmaceutical Policy in Countries with Developing Healthcare Systems

Abstract

Pakistan is a lower middle-income country, and healthcare in the country is regulated by the Ministry of National Health Services Regulation and Coordination. The overall poor performance in health care is reflected in the form of enormous burden of communicable and non-communicable diseases, and high maternal, neonatal and infant mortality rates. These issues are coupled with a reduced health sector investment and a lack of health insurance schemes. There is no pharmacovigilance system, and there are also problems with counterfeit medications. Nevertheless, Pakistan has a dynamic pharmaceutical sector ranking10th largest in the Asia-Pacific region and fulfilling 70% of the country’s medicinal demands. Many finished pharmaceutical products from Pakistan have been deemed acceptable by countries across Asia, Africa and the United States.

Pharmaceutical regulation is governed by the Drug Regulatory Authority of Pakistan (DRAP) which ensures the implementation of the Drugs Act, 1976 (XXXI of 1976). Pakistan’s national essential medicine list (NEML) is based on the WHO standards and promotes generic prescribing; however, this list is generally only followed in the public sector hospitals. The majority of prescribers in the private sector health facilities are influenced by pharmaceutical marketing. There are concerns related to underuse and overuse of certain medicines reflecting an irrational medicines use in the country. There are also policy concerns related to drug pricing due to an absence of a sound medicine pricing formula. A full range of essential drugs is not available in public sector hospitals, either because of inadequate operational budget or due to lack of efficient management. Many consumers in Pakistan can buy medicines without prescription, leading to poor dispensing practices. However, despite numerous issues, the country has shown signs of improvement with regard to healthcare system. The Prime Minister’s National Health Insurance Program initiative, the establishment of drug testing laboratories and the strict punishments for the breach of laws related to medicines’ related offences are few examples that show that the government is serious to improve healthcare.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The World Bank. (2015). Data, land area sq.km. [cited 2015 August 29]. Available from: http://data.worldbank.org/indicator/AG.LND.TOTL.K2

  2. United Nations. (2014). World economic situation and prospects 2014.

    Google Scholar 

  3. Population Action Reference Bureau. (2015). World population data sheet. 2015 [cited 2015 August 29]. Available from: http://www.prb.org/pdf15/2015-world-population-data-sheet_eng.pdf

  4. The World Bank. (2014). Data, urban population (% of total). [cited 2016 April 18]. Available from: http://data.worldbank.org/indicator/SP.URB.TOTL.IN.ZS

  5. The World Bank. (2014). Data, rural population (% of total population). [cited 2016 April 18]. Available from: http://data.worldbank.org/indicator/SP.RUR.TOTL.ZS

  6. Government of Pakistan. (2014). Pakistan economic survey 2014–15. f.d. Economic adviser’s wing (Ed.). Pakistan.

    Google Scholar 

  7. The Global Economy.Com . (2016). Pakistan economic growth. [cited 2016 April 18]. Available from: http://www.theglobaleconomy.com/Pakistan/Economic_growth/

  8. The World Bank. (2014). Data, unemployment, total (% of total labor force). [cited 2016 April 18]. Available from: http://data.worldbank.org/indicator/SL.UEM.TOTL.ZS

  9. Research Development and Solutions. (2012). Health systems governance challenges and opportunities after devolution. Available from: http://www.resdev.org/files/policy_brief/29/29.pdf

  10. World Health Organization. (2015). Health system strengthning. [cited 2015 September 1]. Available from: http://www.emro.who.int/pak/programmes/health-system-strengthening-hss.html

  11. Desk, N. (2015). PM launches national health programme. In The express tribune. The express tribune: Pakistan.

    Google Scholar 

  12. Lorenz, C. (2009). Out-of-pocket household health expenditures and their use in national health accounts: Evidence from Pakistan. Stanford: Stanford University.

    Google Scholar 

  13. Government of Pakistan. (2000). Insurance ordinance, 2000 [Amended upto November 2011]. T.s.a.e.c.o.P. (SECP) (Ed.). Pakistan.

    Google Scholar 

  14. Ahmed, J., & Shaikh, B. T. (2008). An all time low budget for healthcare in Pakistan. Journal of the College of Physicians and Surgeons–Pakistan, 18(6), 388–391.

    PubMed  Google Scholar 

  15. The World Bank. (2014). Life expectancy at birth, total (years).[cited 2016 April 20]. Available from: http://beta.data.worldbank.org/?locations=PK&view=chart

  16. World Health Organization. (2015). Pakistan: WHO statistical profile.

    Google Scholar 

  17. Nishtar, S. (2007). Health indicators of Pakistan gateway paper II (p. 285). Islamabad: Heartfile (non-profit NGO).

    Google Scholar 

  18. The World Bank. (2016). Maternal mortality ratio (modeled estimate, per 100,000 live births). [cited 2016 September 16, 2016]. Available from: http://data.worldbank.org/indicator/SH.STA.MMRT.NE?year_high_desc=false

  19. The World Bank. (2016). Mortality rate, infant (per 1,000 live births). [cited 2016 September 16, 2016]. Available from: http://data.worldbank.org/indicator/SP.DYN.IMRT.IN

  20. The World Bank. (2016). Mortality rate, neonatal (per 1,000 live births). [cited 2016 September 16, 2016]. Available from: http://data.worldbank.org/indicator/SH.DYN.NMRT?name_desc=false

  21. The World Bank. (2016). Mortality rate, under-5 (per 1,000 live births). [cited 2016 September 16]. Available from: http://data.worldbank.org/indicator/SH.DYN.MORT

  22. The Global Polio Eridication Initiative. (2015). Wild poliovirus type 1 and circulating vaccine-derived poliovirus cases. [cited 2015 September 2]. Available from: http://www.polioeradication.org/dataandmonitoring/poliothisweek.aspx

  23. World Health Organization. (2015). Pakistan second endemic country to introduce IPV into routine immunization schedule. [cited 2015 September 2, 2015]. Available from: http://www.emro.who.int/pak/pakistan-news/introduces-ipv-in-routine-immunization.html

  24. National Task Force for Polio Eradication. (2015–2016). National emergency action plan for polio eradication. Government of Pakistan: Pakistan.

    Google Scholar 

  25. World Health Organization. (2015). Dengue fever. [cited 2015 September 2]. Available from: http://www.emro.who.int/pak/programmes/dengue-fever.html

  26. World Health Organization. (2004). The world medicines situation. [cited 2015 September 7]. Available from: http://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf

  27. Zaheer-Ud-Din Babar, S. Q. J., Malik, M. A., & Gilani, A.-H. (2013). The pharmaceutical industry, intellectual property rights and access to medicines in Pakistan. In H. Löfgren & O. D. Williams (Eds.), The new political economy of pharmaceuticals : Production, innovation and TRIPS in the global south (pp. 167–184). London: Palgrave MacMillan.

    Chapter  Google Scholar 

  28. Zaman, K. (2011). Review of Pakistan pharmaceutical industry: SWOT analysis. International Journal of Business & Information Technology, 1(2), 114–117.

    Google Scholar 

  29. Sustainable Development Policy Institute. (2013). India-Pakistan trade : A case study of the pharmaceutical sector (p. 19). Pakistan. Available from: http://www.sdpi.org/.

  30. Ali, M. (2015). Pakistan pharmaceutical market overview. Pakistan. Available from: http://www.slideshare.net/alijehangir/pakistan-pharmaceautical-overivew-2015-57165023/.

  31. Rashid, H. (2015). Impact of the drug regulatory authorityPakistan: An evaluation. New Visions for Public Affairs, 07, 50–61.

    Google Scholar 

  32. Pakistan Pharmaceutical Manufacturer’s Association. (2016). Pakistan pharmaceutical industry. [cited 2016 June 25]. Available from: http://www.ppma.org.pk/Profile/pakistan-pharmaceutical-industry/

  33. Fekete, M. I., et al. (1980). Effects of reserpine and antidepressants on dopamine and DOPAC (3,4-dihydroxyphenylacetic acid) concentrations in the striatum, olfactory tubercle and median eminence of rats. European Journal of Pharmacology, 64(4), 231–238.

    Article  CAS  PubMed  Google Scholar 

  34. Ministry of National Health Services, Regulations and Coordination Government of Pakistan. (2016). Key attached organizations. [cited 2016 September 25]. Available from: http://nhsrc.gov.pk/

  35. The Drug Regulatory Authority of Pakistan. (2015). The drug regulatory authority of Pakistan. [cited 2015 October 1]. Available from: http://www.dra.gov.pk/gop/index.php?q=aHR0cDovLzE5Mi4xNjguNzAuMTM2L2RyYXAv

  36. The Drug Regulatory Authority of Pakistan. (1976). The drugs act, 1976. Available from: http://www.dra.gov.pk/gop/index.php?q=aHR0cDovLzE5Mi4xNjguNzAuMTM2L2RyYXAvdXNlcmZpbGVzMS9maWxlL2RvY3MvVGhlRHJ1Z3NBY3QxOTc2LnBkZg%3D%3D

  37. Ministry of Health. (2010). Pakistan pharmaceutical country profile.

    Google Scholar 

  38. Medical News Pakistan. (2014). No lab for “drug investigation” in the country, In Medical news Pakistan. Medical news Pakistan: The national medical newspaper: Pakistan.

    Google Scholar 

  39. The News Paper’s Staff Correspondent. (2015). Multan drug testing laboratory to be shifted to new building in July. In Dawn. Dawn: Pakistan.

    Google Scholar 

  40. Riaz, A. (2012). Pharmaceuticals: Drug or poison. The Health, 3(2), 36–38.

    Google Scholar 

  41. The Judicial Inquiry Tribunal. (2011–2012). Batch J093 the pathology of neglegence (report of the judicial inquiry tribunal to determine the causes of deaths of patients of the Punjab Institute of Cardiology, Lahore 2011–2012). Pakistan.

    Google Scholar 

  42. Cable News Network. (2015). Pakistan’s fake drugs markets sell medicines made of poison and brick dust. 30 Aug 2015. Available from: http://edition.cnn.com/2015/08/30/asia/pakistan-fake-drugs/

  43. Jaunaidi, I. (2015). Factory producing counterfeit medicine sealed, In Dawn. Dawn: Pakistan.

    Google Scholar 

  44. Staff Reporter. (2013). Counterfeit medicines causing unwarranted deaths, In Pakistan today. Pakistan.

    Google Scholar 

  45. World Health Organization. (2012–2013). WHO-Pakistan biennial report 2012–13.

    Google Scholar 

  46. Hanif, I. (2015). Amended drug act entails stricter penalties for violators, In Dawn. Dawn: Pakistan.

    Google Scholar 

  47. World Health Organization. (2003). National drug policy Pakistan [cited 2015 October 22]. Available from: http://apps.who.int/medicinedocs/en/d/Js17118e/

  48. World Health Organization. (2011). The world medicines situation 2011 (global health trends: Global burden of disease and pharmaceutical needs) (pp. 1–18). Geneva. World Health Organization Press.

    Google Scholar 

  49. Hafeez, A., et al. (2004). Prescription and dispensing practices in public sector health facilities in Pakistan: Survey report. The Journal of the Pakistan Medical Association, 54(4), 187–191.

    CAS  PubMed  Google Scholar 

  50. Zaidi, S., et al. (2013). Access to essential medicines in Pakistan: Policy and health systems research concerns. PLoS One, 8(5), e63515.

    Article  PubMed  PubMed Central  Google Scholar 

  51. World Health Organization. (2002). WHO drug information (p. 243).

    Google Scholar 

  52. World Health Organization. (2014). Pharmaceutical sector assessment survey (level II)–training for data collectors. [cited 2015 October 17]. Available from: http://www.emro.who.int/pakistan-press-releases/2014/training-of-data-collectors-for-pharmaceutical-sector-assessment-survey-psas-level-ii-15-17-september-2014-islamabad-pakistan.html

  53. CIET. (2002). Social audit of governance and delivery of public services: Baseline surver report. Canadian international development agency and National reconstruction bureau of Pakistan: Pakistan.

    Google Scholar 

  54. Aslam, A., et al. (2016). Evaluation of rational drug use at teaching hospitals in Punjab, Pakistan. Journal of Pharmacy Practice and Community Medicine, 2(2), 54–57.

    Article  Google Scholar 

  55. The Drug Regulatory Authority of Pakistan. (2015). Divisions. [cited 2015 October 17, 2015]. Available from: http://www.dra.gov.pk/gop/index.php?q=aHR0cDovLzE5Mi4xNjguNzAuMTM2L2RyYXAvZnJtRGV0YWlscy5hc3B4P29wdD1taXNjbGlua3MmaWQ9NQ%3D%3D

  56. Dawn. (2014). Drug price increase, In Dawn. Dawn: Pakistan.

    Google Scholar 

  57. Haider, M. (2014). Half of Pakistan population lives in poverty: UN report. In The news. The News International: Pakistan.

    Google Scholar 

  58. State Bank of Pakistan. (2015). Inflation monitor September 2015. State Bank of Pakistan: Pakistan.

    Google Scholar 

  59. Mendis, S., et al. (2007). The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization, 85(4), 279–288.

    Article  PubMed  PubMed Central  Google Scholar 

  60. The Network for Consumer Protection. (2006). Prices, availability and affordability of medicines in Pakistan (p. 30). Pakistan.

    Google Scholar 

  61. Quraeshi, Z. A., Luqmani, M., & Malhotra, N. (1982). Brands or generics: The dilemma of pharmaceutical marketing in a developing country. Journal of Health Care Marketing, 3(4), 27–37.

    Google Scholar 

  62. Zafar, S. N., et al. (2008). Self-medication amongst university students of Karachi: Prevalence, knowledge and attitudes. The Journal of the Pakistan Medical Association, 58(4), 214–217.

    PubMed  Google Scholar 

  63. Ullah, H., et al. (2013). Evaluation of self-medication amongst university students in Abbottabad, Pakistan; prevalence, attitude and causes. Acta Poloniae Pharmaceutica, 70(5), 919–922.

    PubMed  Google Scholar 

  64. Hussain, A., & Khanum, A. (2008). Self medication among university students of Islamabad, Pakistan-a preliminary study. Southern Med Review, 1(1), 14–16.

    Google Scholar 

  65. Ahmed, B., et al. (2014). Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: A prospective cohort study. PloS One, 9(11), e112133.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Sabzwari, S. R., Qidwai, W., & Bhanji, S. (2013). Polypharmacy in elderly: A cautious trail to tread. The Journal of the Pakistan Medical Association, 63(5), 624–627.

    PubMed  Google Scholar 

  67. Atif, M., et al. (2016). Assessment of WHO/INRUD core drug use indicators in two tertiary care hospitals of Bahawalpur, Punjab, Pakistan. Journal of Pharmacy Policy Practice, 9, 27.

    Article  Google Scholar 

  68. Zaheer-Ud-Din Babar, S. J. (2008). Social pharmacy strengthening clinical pharmacy: Why pharmaceutical policy research is needed in Pakistan? Pharmacy World & Science, 30(5), 617–619.

    Article  Google Scholar 

  69. Hussain, A., Malik, M., & Toklu, H. Z. (2013). A literature review: Pharmaceutical care an evolving role at community pharmacies in Pakistan. The Journal of Pharmacy and Pharmacology, 4(5), 425–430.

    Article  Google Scholar 

  70. Elahi, A. (2013). Health facilities for rural Pakistan. [cited 2016 April 6]. Available from: http://www.heartfile.org/blog/1038

  71. Khalid, L., Mahsood, N., & Ali, I. (2016). The public health problem of OTC antibiotics in developing nations. Research in Social & Administrative Pharmacy, 12(5), 801–802.

    Article  Google Scholar 

  72. Zafar, S. N., et al. (2008). Prescription of medicines by medical students of Karachi, Pakistan: A cross-sectional study. BMC Public Health, 8(1), 1–7.

    Article  Google Scholar 

  73. Haseeb, A., & Bilal, M. (2016). Prevalence of using non prescribed medications in economically deprived rural population of Pakistan. Archives of Public Health, 74(1), 1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  74. The Aga Khan University Hospital. (2016). World class quality health services. [cited 2016 June 26]. Available from: https://hospitals.aku.edu/pakistan/AboutUs/Pages/world-class-quality-health-services.aspx

  75. Shaukat Khanum Memorial Cancer Hospital and Research Centre. (2016). Pharmacy. [cited 2016 june 26]. Available from: https://www.shaukatkhanum.org.pk/patientcare/clinical-services/161.html

  76. Government of Pakistan. (2007). National essential medicines list of Pakistan. Ministry of Health Government of Pakistan (Ed.). Pakistan.

    Google Scholar 

  77. Shamimulhaq, S., et al. (2014). Factors influencing prescription behavior of physicians. Journal of Pharmaceutical Innovation, 2277–7695.

    Google Scholar 

  78. Hussain, S., et al. (2011). Pharmacoepidemiological studies of prescribing practices of health care providers of Pakistan: A cross-sectional survey. African Journal of Pharmacy and Pharmacology, 5(12), 1484–1493.

    Article  Google Scholar 

  79. Siddiqi, S., et al. (2002). Prescription practices of public and private health care providers in Attock District of Pakistan. The International Journal of Health Planning and Management, 17(1), 23–40.

    Article  CAS  PubMed  Google Scholar 

  80. Ahmad, M., et al. (2011). Ethical evaluation of pharmaceutical marketing in Pakistan. Acta Bioethica, 17(2), 215–224.

    Google Scholar 

  81. Khan, T. M. (2010). Glimpse of pharmacy education in Pakistan and current challenges to pharmacy education. International Journal of Pharmacy Teaching & Practices, 1(1), 5–10.

    Google Scholar 

  82. Recognition Status of Pharmacy Institutions. (2011). Recognition status of pharmacy institutions. [cited 2016 April 6]. Available from: http://www.pharmacycouncil.org.pk/PI.php

  83. Khan, T. (2011). Challenges to pharmacy and pharmacy practice in Pakistan. Australasian Medical Journal, 4(4), 230–235.

    Article  PubMed Central  Google Scholar 

  84. Pharmacy Act. (1967). Pharmacy act 1967. Pakistan.

    Google Scholar 

  85. Azhar, S., et al. (2009). The role of pharmacists in developing countries: The current scenario in Pakistan. Human Resources for Health, 7(1), 54.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Mujeeb, R. (2013). To be a pharmacist in Pakistan. In The express tribune. The Express Tribune: Pakistan.

    Google Scholar 

  87. Hussain, K., et al. (2003). The pharmacy Act XI of 1967: Quackery and irrational use of drugs. Pakistan Journal of Pharmacology, 2006, 16–19.

    Google Scholar 

  88. Clinix. (2016). Clinix. [cited 2016 September 25]. Available from: http://clinixplus.com/

  89. Green Plus Pharmacie. (2016). Services provided by Green Plus Pharmacie. [cited 2016 September 25]. Available from: http://www.greenpluspharmacie.com/services.html

  90. Servaid Pharmacy. (2016). Servaid pharmacy. [cited 2016 September 25]. Available from: http://www.servaid.com.pk/

  91. World Health Organization. (2003). Introduction to drug utilization research (p. 49). World Health Organization: Geneva.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

    Muhammad Atif, Mahmood Ahmad, Quratulain Saleem & Muhammad Qamar-uz-Zaman

  2. School of Pharmacy, University of Auckland, Auckland, New Zealand

    Louise Curley

  3. Department of Pharmacy, School of Applied Sciences, University of Huddersfield, HD1 3DH, Huddersfield, United Kingdom

    Zaheer-Ud-Din Babar

  4. Faculty of Medical and Health Sciences, School of Pharmacy, University of Auckland, Private Mail Bag 92019, Auckland, New Zealand

    Zaheer-Ud-Din Babar

Authors
  1. Muhammad Atif
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmood Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quratulain Saleem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louise Curley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Qamar-uz-Zaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zaheer-Ud-Din Babar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Atif .

Editor information

Editors and Affiliations

  1. Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, New Zealand

    Zaheer-Ud-Din Babar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Atif, M., Ahmad, M., Saleem, Q., Curley, L., Qamar-uz-Zaman, M., Babar, ZUD. (2017). Pharmaceutical Policy in Pakistan. In: Babar, ZUD. (eds) Pharmaceutical Policy in Countries with Developing Healthcare Systems. Adis, Cham. https://doi.org/10.1007/978-3-319-51673-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51673-8_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-51672-1

  • Online ISBN: 978-3-319-51673-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation